

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/551,374
				Filing Date	(Int'l) April 2, 2004
				First Named Inventor	Andrew S. JANOFF
				Art Unit	Not Yet Assigned 1636
				Examiner Name	Not Yet Assigned Hibbert
Sheet	1	of	1	Attorney Docket Number	532552001100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					¹ ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/C.H./	1.	BARRIERE et al., Pharmacotherapy (1992) 12:397-402			
/C.H./	2.	BEPLER et al., Cancer Research (1986) 46(7):3413-3419			
/C.H./	3.	BLUMENTHAL et al., International Journal of Cancer (2004) 108:293-300			
/C.H./	4.	BONNER and KOZELSKY, Cancer Chemother. Pharmacol. (1990) 39:109-112			
/C.H./	5.	FREI et al., Clin. Cancer Res. (1998) 4:2027-2037			
/C.H./	6.	HOFS et al., Anticancer Drugs (1994) 5:35-42			
/C.H./	7.	International Search Report for PCT/US2004/010388, mailed on October 7, 2004, 5 pages			
/C.H./	8.	KANZAWA et al., Int. J. Cancer (1997) 71(3):311-319			
/C.H./	9.	OSAKI et al., Cancer Gene Therapy (2000) 7(2):300-307			
/C.H./	10.	PEROU et al., Nature (2000) 406(6797):747-752			
/C.H./	11.	SCHIMPFF, Support Care Cancer (1993) 1:15-18			
/C.H./	12.	SHAH and SCHWARTZ, Clin. Cancer Res. (2001) 7:2168-2181			
/C.H./	13.	SHLAES et al., Clin. Infect. Dis. (1993) 17:S527-S536			
/C.H./	14.	SWAFFAR et al., Anti-Cancer Drugs (1995) 6:586-593			
/C.H./	15.	TODD et al., J. Clin. Oncol. (1984) 2:986-993			
/C.H./	16.	VANT VEER et al., Nature (2002) 415:530-536			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Catherine Hibbert/	Date Considered	10/30/2008
--------------------	---------------------	-----------------	------------

sd-286089